Chimeric antigen receptor–based therapies beyond cancer

zu Verbundenen Objekten

Abstract: Adoptive cell transfer (ACT) therapies have gained renewed interest in the field of immunotherapy following the advent of chimeric antigen receptor (CAR) technology. This immunological breakthrough requires immune cell engineering with an artificial surface protein receptor for antigen‐specific recognition coupled to an intracellular protein domain for cell activating functions. CAR‐based ACT has successfully solved some hematological malignancies, and it is expected that other tumors may soon benefit from this approach. However, the potential of CAR technology is such that other immune‐mediated disorders are beginning to profit from it. This review will focus on CAR‐based ACT therapeutic areas other than oncology such as infection, allergy, autoimmunity, transplantation, and fibrotic repair. Herein, we discuss the results and limitations of preclinical and clinical studies in that regard.

Standort
Deutsche Nationalbibliothek Frankfurt am Main
Umfang
Online-Ressource
Sprache
Englisch

Erschienen in
Chimeric antigen receptor–based therapies beyond cancer ; day:06 ; month:02 ; year:2023 ; extent:11
European journal of immunology ; (06.02.2023) (gesamt 11)

Urheber
Velasco‐de Andrés, María
Muñoz‐Sánchez, Guillermo
Carrillo‐Serradell, Laura
Gutiérrez‐Hernández, María del Mar
Català, Cristina
Isamat, Marcos
Lozano, Francisco

DOI
10.1002/eji.202250184
URN
urn:nbn:de:101:1-2023020714035114077274
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:56 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Velasco‐de Andrés, María
  • Muñoz‐Sánchez, Guillermo
  • Carrillo‐Serradell, Laura
  • Gutiérrez‐Hernández, María del Mar
  • Català, Cristina
  • Isamat, Marcos
  • Lozano, Francisco

Ähnliche Objekte (12)

Chimeric antigen receptor T cell therapies for multiple myeloma

Chimeric antigen receptor T cell therapies for multiple myeloma

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies

Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies

Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice

Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice

Chimeric Antigen Receptor T-Cell Therapy

Chimeric Antigen Receptor T-Cell Therapy

Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies

Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies

Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma

Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma

Engineering better chimeric antigen receptor T cells

Engineering better chimeric antigen receptor T cells

Optimization of chimeric antigen receptor (CAR) therapy

Optimization of chimeric antigen receptor (CAR) therapy

Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity

Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance

Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future

Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future

Verbundene Objekte